Targeting human epidermal growth factor receptor 2 enhances radiosensitivity and reduces the metastatic potential of Lewis lung carcinoma cells
Open Access
- 6 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Radiation Oncology
- Vol. 15 (1), 1-11
- https://doi.org/10.1186/s13014-020-01493-8
Abstract
Sublethal radiation induces matrix metalloproteinase 9 (MMP-9)-mediated radioresistance in Lewis lung carcinoma (LLC) cells and their metastatic dissemination. We aim to determine if EGFR/HER2 activation associates with MMP-9-mediated radioresistance and invasiveness in irradiated LLC cells. LLC cells were treated with erlotinib or afatinib followed by sublethal radiation. After irradiation, we examined the phosphorylation of EGFR/HER2 and MMP-9 expression. Colony formation assay determined if the kinase inhibitors sensitize LLC cells to radiation. Matrigel-coated Boyden chamber assay assessed cellular invasiveness. Resulting tumors of wild-type LLC cells or HER2 knock-down mutant cells were irradiated to induce pulmonary metastases. Afatinib more effectively sensitized LLC cells to radiation and decreased invasiveness by inhibiting phosphorylation of EGFR, HER2, Akt, ERK, and p38, and down-regulating MMP-9 when compared to erlotinib. Afatinib abolished radiation-induced lung metastases in vivo. Furthermore, LLC HER2 knock-down cells treated with radiation had growth inhibition. Dual inhibition of radiation-activated EGFR and HER2 signaling by afatinib suppressed the proliferation and invasion of irradiated LLC cells. Increased radiosensitivity and decreased metastatic dissemination were observed by pharmacological or genetic HER2 inhibition in vivo. These findings indicate that HER2 plays a pivotal role in enhancing radioresistance and reducing metastatic potential of LLC cells.Keywords
This publication has 40 references indexed in Scilit:
- Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cellsMolecular Cancer, 2013
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic PerspectivesJournal of Clinical Oncology, 2013
- TMARKER: A free software toolkit for histopathological cell counting and staining estimationJournal of Pathology Informatics, 2013
- Application of whole slide image markup and annotation for pathologist knowledge captureJournal of Pathology Informatics, 2013
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancerOncogene, 2011
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapyFEBS Letters, 2010
- Molecular mechanisms underlying ErbB2/HER2 action in breast cancerOncogene, 2000
- Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinicJournal of Clinical Immunology, 1991